2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor
  5. TXA2/TP Isoform
  6. TXA2/TP Inhibitor

TXA2/TP Inhibitor

TXA2/TP Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-100441
    Treprostinil
    		Inhibitor 99.98%
    Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
  • HY-N0607
    Ginsenoside Ro
    		Inhibitor 99.81%
    Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 ?μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
  • HY-B0428
    Ozagrel
    		Inhibitor 99.74%
    Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
  • HY-B0428B
    Ozagrel hydrochloride
    		Inhibitor 99.68%
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM.
  • HY-B0428A
    Ozagrel sodium
    		Inhibitor 99.98%
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
  • HY-B1735
    Picotamide
    		Inhibitor 99.66%
    Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases.
  • HY-118014
    CAY10535
    		Inhibitor
    CAY10535 is a FP and TP receptor inhibitor and can be used for research of cardiovascular diseases.
  • HY-101606
    Etersalate
    		Inhibitor
    Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.
  • HY-124150
    BM567
    		Inhibitor
    BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively.